How research helped lead to FDA approval of a pediatric neuroblastoma drug

The drug, called eflornithine (DFMO) and newly branded as IWILFIN by US WorldMeds, reduces the risk of relapse for pediatric high-risk neuroblastoma patients achieving at least a partial response after multiagent, multimodality therapy including immunotherapy by more than 50%.

Read more: https://medicalxpress.com/news/2023-12-fda-pediatric-neuroblastoma-drug.html